

Production of recombinant enzymes of wide use for research

María J. Manzur

Departamento de Bioquímica y Ciencias Biológicas
Facultad de Química, Bioquímica y Farmacia
Universidad Nacional de San Luis
Ejército de los Andes 950
San Luis, Argentina
Tel/Fax: 54 2652 422644
E-mail: mjmanzu@unsl.edu.ar

Rosana V. Muñoz

Departamento de Bioquímica y Ciencias Biológicas
Facultad de Química, Bioquímica y Farmacia
Universidad Nacional de San Luis
Ejército de los Andes 950
San Luis, Argentina
Tel/Fax: 54 2652 422644
E-mail: munoz@bio.puc.cl

Adrián A. Lucero

Departamento de Bioquímica y Ciencias Biológicas
Facultad de Química, Bioquímica y Farmacia
Universidad Nacional de San Luis
Ejército de los Andes 950
San Luis, Argentina
Tel/Fax: 54 2652 422644
E-mail: adrian_lucerhoff@yahoo.com

Maximiliano Juri Ayub

Departamento de Bioquímica y Ciencias Biológicas
Facultad de Química, Bioquímica y Farmacia
Universidad Nacional de San Luis
Ejército de los Andes 950
San Luis, Argentina
Tel/Fax: 54 2652 422644
E-mail: juriayub@dna.uba.ar

Sergio E. Alvarez

Departamento de Bioquímica y Ciencias Biológicas
Facultad de Química, Bioquímica y Farmacia
Universidad Nacional de San Luis
Ejército de los Andes 950
San Luis, Argentina
Tel/Fax: 54 2652 422644
E-mail: sealvar@unsl.edu.ar

Gladys M. Ciuffo*

Departamento de Bioquímica y Ciencias Biológicas
Facultad de Química, Bioquímica y Farmacia
Universidad Nacional de San Luis
Ejército de los Andes 950
San Luis, Argentina
Tel/Fax: 54 2652 422644
E-mail: gciuffo@unsl.edu.ar

Financial support: Grant from the Universidad Nacional de San Luis, Argentina.

Keywords: bioactivity, protein expression, purification, recombinant enzymes.

* Corresponding author

Abbreviations: Ang II: Angiotensin II
 AT₂: Angiotensin II type 2 receptor
 GAPDH: Glyseraldehyde-3-phosphate dehydrogenase
 MMLV: Moloney murine Leukemia Virus
 PND: post-natal day
 SN: supernatant

For biotechnological purposes, protein expression refers to the directed synthesis of large amounts of desired proteins. The aim of the present work was to produce reverse transcriptase Moloney murine Leukaemia Virus retro-transcriptase and *Taq* DNA polymerase, as bioactive products. In the present paper, we report the preparation of recombinant enzymes, expressed in *E. coli* strains. The enzymes produced exhibited quite good activity, compared with commercial enzymes, allowing us to replace the last ones for several lab applications. We are reporting changes and modifications to standard protocols described. The standard protocols were modified, *i.e.* for the purification step of *Taq*, a temperature dependent procedure was designed. The enzymes produced were used in different applications, such as PCR, RT-PCR, PCR Multiplex and RAPDs molecular markers.

to manipulate DNA in defined ways (Thatcher and Hitchcock, 1994). The major tools for genetic engineering are the enzymes that catalyze specific reactions on DNA/RNA molecules. *Taq* DNA polymerase and Moloney murine Leukaemia Virus (MMLV) retrotranscriptase are widely used enzymes for research in laboratories applying molecular biology methods. Recombinant enzymes are available in the market but at high prices. To reduce the cost of lab experiences, we made the effort to produce our own recombinant enzymes.

The success of modern biotechnology results from the ability to express foreign or heterologous genes in a host organism. However, transcription and translation of a recombinant gene do not always lead to the accumulation of a folded fully active protein (Price and Stevens, 1999). It is well-known that artificially induced abnormal proteins, as well as foreign proteins accumulate in an insoluble state, known as inclusion bodies, which contain almost pure protein held together by non covalent force which could only be solubilized with strong denaturing agents (Thatcher and Hitchcock, 1994). The biotechnology challenge is to exploit the inclusion body phenomenon, and to convert the

Protein expression refers to the directed synthesis of large amounts of desired proteins. Many of the revolutionary changes that have occurred in the biological sciences over the past 15-20 years can be directly attributed to the ability




Figure 1. Purification of *Taq* polymerase and activity assay.

(a) SDS-PAGE (12.5%) of aliquots of the preparation at different purification steps. Lane 1: solubilized proteins after 11 hrs of IPTG (1 mM) induction. Lane 2: SN obtained after the sonication step. Lane 3: proteins remaining after purification by heat.
 (b) SDS-PAGE (12.5%, silver staining) of the commercial (lane 1) and produced (lane 2) *Taq* polymerase.
 (c) Amplification products of the AT₂ Ang II receptor, obtained with the produced *Taq* polymerase (lanes 1-8) and commercial one (lanes 9-10). Lanes 1-8: volumes of *Taq* employed (µl): 1 (0.3), 2 (0.4), 3 (0.5), 4 (0.6), 5 (0.7), 6 (0.8), 7 (0.9), 8 (1). Lanes 9-10: 0.3 and 0.4 µl, commercial *Taq*. MW: molecular weight ladder, 1 kb.

protein encapsulated into a useful bioactive product. It has been suggested that protein deposited in these inclusions are aggregates of misfolded protein (Bowden et al. 1991; Chaffotte et al. 1992; Thatcher and Hitchcock, 1994).

The aim of the present work was to produce reverse transcriptase MMLV and *Taq* DNA polymerase, as bioactive products. Thus, we set up a protocol for the expression of recombinant proteins in *E. coli* to obtain enzymes of high purity and specific activity. We are reporting changes and modifications to standard protocols described in the literature (Engelke et al. 1990; Pluthero, 1993; Ottino, 1998; Taube, 1998).

MATERIALS AND METHODS

Standard protocols were used for the production of recombinant proteins including the following steps.

Transformation of competent cells

Competent cells were generated starting from the strain *E. coli* DH5 α and BL21(DE3) by using the CaCl₂ standard protocol (Ausubel et al. 1999). Competent cells were transformed using the vector pTTQ18 containing the sequence of *Taq* with a selection marker for Ampiciline (Amp) and a vector containing the MMLV sequence and selection markers for Chloranfenicol and Kanamycine (both vectors were generously provided by Ing. Masuelli, Fac. Cs. Agrarias, Mza). Transformation was carried out by thermic shock: competent bacteria were incubated with the vector 10 min on ice, followed by incubation at 42°C for 2 min and a final step at 4°C. The transformants were resuspended in 500 μ l of culture media containing

antibiotics, spread on a plate and incubated at 37°C.

Expression induction with IPTG

Induction was performed for different times with Isopropil β -thiogalactoside (IPTG, 1 mM) in the appropriate culture media. Expression was controlled by analyzing aliquots of material obtained at the different steps by SDS-PAGE (12%). Once the best conditions for time, IPTG concentration and other variables were set up, a larger scale culture was performed, which was used for protein purification (Lawyer et al. 1989; Bollag et al. 1996; Ausubel et al. 1999).

Purification

Purification of *Taq* polymerase. To purify *Taq* polymerase we took advantage of the resistance of the enzyme to high temperatures and designed a purification based on heating. The *pellet* of bacteria was resuspended in PBS with 4 mg/ml of lysozyme and the mixture was exposed to several cycles of frozen/melting steps to favour cellular breakage. After sonication (3 pulses), cellular lysates were centrifuged and the supernatant (SN) recovered. The SN was heated at 72°C for 1 hr and then centrifuged at 15000 xg, *Taq* polymerase remains in the SN. Purified proteins were dialyzed against storage buffer (50 mM Tris-HCl pH = 8, 100 mM NaCl, 0.1 mM EDTA y 2 mM β -mercaptoethanol), in two steps, lasting three days. Sterile glycerol was added to the dialyzed material to a final concentration of 50% to cryoprotect the enzyme and stored at -20°C. Reaction buffer (10 x) free of Mg was prepared (10 mM Tris-HCl (pH 9.0), 50 mM KCl and 0.1%, Triton X-100).




Figure 2. Purification of the retrotranscriptase.

(a) Induced over expression of MMLV in SN and inclusion bodies SDS-PAGE gels (7.5%), stained with CBB.

(b) Purification from inclusion bodies and dialysis with different triton X-100 concentrations. SDS-PAGE gels (7.5%), stained with CBB.

MMLV purification. Bacterial slurry was centrifuged at 4000 rpm for 10 min and the pellet was resuspended in 30 ml wash buffer (50 mM Na₂HPO₄ pH 8, 0.3 M NaCl, 5 mM 2-mercaptoethanol). Cellular lysis was achieved by treatment with lysozyme 1 mg/ml and sonication as described above. Aliquots were centrifuged at 5000 xg for 15 min. SDS-PAGE analysis indicates that the protein of interest was present in the soluble fraction as well as in the inclusion body fraction. Inclusion bodies were resuspended in wash buffer containing 0%, 0.5% and 2% of Triton X-100. Three washes with Triton X-100, followed by 3 washes without detergent were performed. The *pellet* was resuspended in 1 ml of solubilization buffer (50 mM Tris pH 8, 8 M Urea, 0.3 M NaCl, 5 mM 2-β-mercaptoethanol). Following centrifugation (12000 xg, 1 hr) the SN was diluted in solubilization buffer and protein was renatured by dialysis at 4°C against 50-100 V of renaturation buffer. The dialyzed material was centrifuged at 13000 xg (1 hr) and the SN resuspended with the same volume of glycerol and stored at -20°C.

Activity assays

The enzymatic activity was verified by means of different RT or PCR assays, using variable conditions: enzyme volume, MgCl₂ concentrations, etc.

PCR. Aliquots of DNA from adult rat kidney were used to amplify the AT₂ receptor subtype of Ang II, following standard protocols to amplify the fragment of interest (Dieffenbach and Dveksler, 1995; Nickenig et al. 1997).

RT-PCR assay. RNAs obtained from cerebellum of different ages (TRIzol, GIBCO) were used to produce cDNA by retrotranscription in a first step (RT) and then amplification was conducted for AT₂ and GAPDH fragments by PCR assays as described (Ciuffo et al. 1996).

RFLP. Amplification products were digested with the indicated enzymes.




Figure 3. RT-PCR co-amplification by PCR Multiplex. Co-amplification of AT₂ receptor (586 bp) and GAPDH (350 bp) in cerebellum at different developmental stages. Upper Panel: PND0 (PND: post-natal day) and PND4. Lower Panel: PND8 to PND60. Etidium bromide staining. Experiment representative of four independent experiences. C+: positive control.

RESULTS AND DISCUSSION

Following the procedures described under Methods, the recombinant enzymes were expressed and purified from *E. coli* DH5α and BL21 cultures (Figure 1 and Figure 2). Figure 1 shows the purification steps followed to produce *Taq* polymerase enzyme (SDS-PAGE, Coomassie staining). Figure 1b shows the silver staining of the commercial and the *Taq* polymerase obtained in this work. In order to test the enzymatic activity of the enzyme we performed amplification of the AT₂ receptor with a commercial enzyme and compare with the amplification of AT₂ receptor with increasing amounts (0.3 to 1 μl) of the produced enzyme, following a previously described PCR protocol (Ciuffo et al. 1996). Figure 1c shows amplification products for the AT₂ receptor (586 bp) with all the enzyme volumes used, having a more specific amplification product with the prepared enzyme. A well-defined band of the expected size was obtained with our enzyme. The signal obtained with 0.4 μl of the enzyme was comparable to the one obtained with 0.3 μl of the commercial enzyme. From these experiences, the estimated specific activity was 2-5 U/μl. In order to determine the best assay conditions, variable concentrations of MgCl₂ were included in the reaction mixture (data not shown).

Figure 2 shows the over-expression of MMLV (65 kDa) either in the soluble fraction (SN) or in the inclusion bodies (pellet), with a higher yield in the inclusion bodies (Figure 2a). From the soluble material the enzyme was purified by using His-tag affinity chromatography. However, a higher yield was obtained by purification starting from the inclusion bodies. While most of the authors purify the enzyme from the soluble material (Sun et al. 1998; Taube et al. 1998), we decided to pursue the purification from the inclusion bodies. In Figure 2b it can be observed that a concentration of Triton X-100 0% to 0.5% gives a better yield on the purification process than a 2% of Triton X-100.

Recombinant enzymes obtained in the lab were used to perform different amplification assays by using DNA from variable sources, such as animal (Figure 1c), vegetal or viral origin with excellent results (Pungitore et al. 2004).

Figure 3 shows an example where we analyzed the expression of two different genes by RT-PCR in a single assay (Multiplex PCR): simultaneous amplification was performed for the Ang II AT₂ receptor (586 bp) and GAPDH (350 bp) genes, the second used as control. Both steps, the RT and the PCR were performed with the enzymes produced in the lab. These assays allow us to confirm that both enzymes are functional, since co-amplification of the two target sequences was achieved. Different development stages were analyzed and a change in the expression level of AT₂ receptor was observed with maximum expression at PND15, in agreement with previous results obtained by autoradiography (Arce et al. 2001) (Figure 3).

The identity of the AT₂ receptor fragment (586 bp) amplified from rat kidney DNA with our enzyme, was verified performing a restriction fragment length polymorphism (RFLP). Figure 4 shows the digestion products of the 586 bp fragment with two different enzymes. Fragments of the expected size were obtained, thus indicating the correct identity of the amplified fragment of AT₂ receptor.

When the goal is to express proteins as a reagent in biochemical or cell biology experiments, the authenticity of the protein function, such as high specific enzymatic activity is very important. The present results show that the enzymes obtained had their specific activity proved in different system and complex reactions such as the Multiplex RT-PCR.

Taq polymerase was a soluble protein, a fact that simplifies the purification protocol. Most of the published protocols include a purification step by precipitation with NH₄SO₄ (Engelke et al. 1990; Ottino, 1998). The novelty of the present purification protocol is that we took advantage of the resistance to high temperature of *Taq* polymerase. At 72°C most proteins were denatured and precipitated while *Taq polymerase* remained in solution. For the dialysis step we used β-mercaptoethanol instead of the recommended dTT, to protect the enzyme structure (Engelke et al. 1990; Ottino, 1998).




Figure 4. RFLP of the AT₂ amplified fragment. Lane 1: AT₂ fragment digested with *PvuII*. Lane 2: digestion with *SspI*. C: control product. MW molecular weight marker (100 bp ladder).

Different approaches were used to purify MMLV retrotranscriptase, however, in this paper the best results were obtained from the inclusion body fraction, while most of the authors use the soluble fraction. The level of accumulation and the chemical agent used to solubilize the inclusion bodies will be the major factors influencing the choice of refolding strategy. Since MMLV is a protein of a relatively small molecular weight (65 kDa) we could recover the protein by slow dialysis which seems to be more appropriate than a rapid dilution of the denaturant. Another advantage of the inclusion bodies is that they can be stored at -80°C and the enzyme recovered later.

In summary, we are reporting modified protocols for the expression and purification of both *Taq* polymerase and MMLV retrotranscriptase with a high yield and good

specific activity as shown by different assays performed.

ACKNOWLEDGMENTS

M. Juri Ayub and S.E. Alvarez, have fellowships from CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas, Arg). We thank to Dr. R. Masuelli for helpful suggestions. G.M. Ciuffo is a member of the CONICET researcher career.

REFERENCES

- ARCE, M.E.; SANCHEZ, S.; SELTZER, A. and CIUFFO, G.M. Autoradiographic localization of angiotensin II receptors in developing rat cerebellum and brainstem. *Regulatory Peptides*, 2001, vol. 99, no. 1, p. 53-60.
- AUSUBEL, Frederick M.; BRENT, Roger.; KINGSTON, Robert E.; MOORE, David D.; SEIDMAN, S.J.; SMITH John A. and STRUHL, Kevin. *Short protocols in molecular biology*. 4th ed. Wiley, USA, 1999. 1104 p. ISBN 0-471-32938-X.
- BOLLAG, D.M.; ROZYCKI, M.D. and EDELSTEIN, S.J. *Protein methods*. Wiley-Liss USA. 2nd ed. 1996. 432 p. ISBN 0-471-11837-0.
- BOWDEN, G.A.; PAREDES, A.M. and GEORGIU, G. Structure and morphology of protein inclusion bodies in *E. coli*. *Bio/Technology*, 1991, vol. 9, p. 725-730.
- CHAFFOTTE, A.F.; GUILLOU, Y. and GOLDBERG, M.E. Inclusion bodies of the thermophilic endoglucanase D from *Clostridium thermocellum* are made of native enzyme that resist 8M urea. *European Journal of Biochemistry*, 1992, vol. 205, p. 369-373.
- CIUFFO, G.M.; JOHREN, O., EGIDY, G.; HEEMSKERK, F.M.J. and SAAVEDRA, J.M. Heterogeneity of rat Ang II AT₂ receptors. In: RAIZADA, M.; PHILLIP, I. and SUMMERS, C. eds. *Recent Advances in Angiotensin Receptors*. Plenum Press, 1996, p. 189-197.
- DIEFFENBACH, C.W. and DVEKSLER, G.S. *PCR Primer. A laboratory manual*. Cold Spring Harbour: Laboratory Press, 1995. ISBN 0-87969-447-5.
- ENGELKE, D.R.; KRISKOS, A.; BRUCK, M.E. and GINSBURG, D. Purification of *Thermus aquaticus* DNA polymerase expressed in *Escherichia coli*. *Analytical Biochemistry*, 1990, vol. 191, no. 2, p. 396-400.
- LAWYER, F.C.; STOFFEL, S.; SAIKI, R.K.; MYAMBO, K.; DRUMMOND, R. and GELFAND, D.H. Isolation, characterization, and expression in *Escherichia coli* of the DNA polymerase gene from *Thermus aquaticus*. *Journal of Biological Chemistry*, 1989, vol. 264, no. 11, p. 6427-6437.
- NICKENIG, G.; SACHINIDIS, A.; MICHAELSEN, F.;

BOHM, M.; SEEWALD, S.; VETTER, H. Upregulation of vascular Angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. *Circulation*, 1997, vol. 95, no. 2, p. 473-478.

OTTINO, P. Rapid purification of high activity *Taq* DNA polymerase expressed in transformed *E. coli* cells. *Transactions of the Zimbabwe Scientific Association*, 1998, vol. 72, p. 23-26.

PUNGITORE, C.R.; AYUB, M.J.; BORKOWSKI, E.J.; TONN C.E. and CIUFFO G.M. Inhibition of *Taq* DNA polymerase by catalpol. *Cellular and Molecular Biology*, 2004, vol. 50, no. 6, p. 767-772.

PRICE, N.C. and STEVENS, L. The purification of enzymes. In: *Fundamentals of enzymology: The cell and molecular biology of catalytic proteins*. Oxford University Press, 1999, p. 15-46.

PLUTHERO, F.G. Rapid purification of high-activity *Taq* DNA polymerase. *Nucleic Acids Research*, 1993, vol. 21, no. 20, p. 4850-4851.

SUN, D.; JESSEN, S.; LIU, C.; LIU, X; NAJMUDIN, S. and GEORGIADIS, M.M. Cloning, expression, and purification of a catalytic fragment of Moloney murine leukaemia virus reverse transcriptase: Crystallization of nucleic acid complexes. *Protein Science*, 1998, vol. 7, no. 7, p. 1575-1582.

TAUBE, R.; LOYA, S.; VIDAN, O.A.; PERACH, M. and HIZI, A. Reverse transcriptase of mouse mammary tumour virus: expression in bacteria, purification and biochemical characterization. *Biochemical Journal*, 1998, vol. 329, no. 3, p. 579-587.

THATCHER, D.R. and HITCHCOCK, A. Protein folding in biotechnology. In: PAIN, R.H. ed. *Mechanism of Protein Folding*. Oxford University Press, 1994. p. 229-261.